Articles from:October 2026

  • Mainstage production to take audiences on complex journey through addiction

    MEDIA RELEASE – Oct. 26, 2026 — R0096

    Brock University’s Department of Dramatic Arts (DART) is exploring the world of addiction and mental health to bring a compelling story of struggle and hope to the stage.

    People, Places and Things, written by British playwright Duncan Macmillan and directed by DART Associate Professor Danielle Wilson, opens Friday, Nov. 6 at the Marilyn I. Walker Theatre in downtown St. Catharines.

    When Wilson first read the play a decade ago, she was struck by its brilliance and immediately knew she wanted to bring the story to life. First performed in 2015 at the National Theatre in London, U.K., the play is acclaimed for its portrayal of substance abuse and mental health.

    “People, Places and Things is just as relevant now as it was 10 years ago. All we have to do is look around our own communities, and across Canada, to see the reach of addiction,” she says. “This play provides an opportunity to open discussion on a difficult topic.”

    Both dark and humorous, Brock’s production takes audiences on a physical and theatrical journey through the main character Emma’s detox, denial and relapse as well as the struggle to recover her mental and physical health.

    Embodied storytelling is central to the production, with movement choreographed by theatre artist Trevor Copp used to highlight Emma’s mental, emotional and physical state.

    For Wilson, that approach makes the piece true theatre — a story that can only ever be fully told on stage.

    “The playwright understands movement and how it adds complexity to a scene,” she says. “Rather than telling us how the characters are feeling, we experience their inner state through their movements and physicality.”

    The creative process of mounting the production — from script analysis, staging, lighting, wardrobe and building the set — has created a safe space for students to explore the impact of addiction on individuals and communities.

    “There can be a lot of judgment, but now we might have a second thought about what may be going on in a person’s life that has led them to that place when we encounter someone experiencing addiction,” says Wilson, who invited community members with lived experience of addiction to share their stories with students.

    For fourth-year DART student Jenna Fortier who plays the lead role of Emma, understanding the lives of the characters is a reminder that everyone has their own story.

    “Addiction isn’t rare and isn’t indicative of some moral failure. These are people who are trying to survive a complicated world; I wonder when society decided to replace support with shame,” Fortier says.

    “I am so grateful for the courageous people who’ve shared their most painful, vulnerable and triumphant moments with our cast,” says second-year DART student and mainstage actor Deborah Howey. “This has supported us in telling their stories with the care and respect that it deserves.”

    Implementing wellness practices and ensuring students are supported while engaging with difficult subject matter have been a top priority for Wilson.

    “This process has helped us all build kindness and empathy,” she says. “What makes this play so brilliant is that it also has humour and lightness in it — we cannot always sit in the dark.”

    People, Places and Things opens Friday, Nov. 6 at 7:30 p.m. at the Marilyn I. Walker Theatre in the Marilyn I. Walker School of Fine and Performing Arts in downtown St. Catharines. Performances will also take place Saturday, Nov. 7 at 7:30 p.m., Sunday, Nov. 8 at 2 p.m., Thursday, Nov. 12 at 7:30 p.m., Friday, Nov. 13 at 7:30 p.m. and Saturday, Nov. 14 at 7:30 p.m.

    General admission tickets are $25 and tickets for students and seniors are $20. Visit Brock University Tickets to reserve seats.

    For more information or for assistance arranging interviews: 

    *Melinda Cheevers, Communications Specialist, Brock University, [email protected] or 289-241-5855

    – 30 –

    Categories: Media releases

  • Researchers exploring new ways to monitor breast cancer, reducing demand for imaging tests

    MEDIA RELEASE – Oct. 22, 2026 — R0095

    Breast cancer patients need to undergo mammograms or other imaging tests to ensure tumours haven’t gro wn or reappeared following surgery and during chemotherapy.

    But some of these imaging tests — particularly those involving radiation — carry risks to long-term health, are expensive to use or are in high demand causing delays in access, says Anna Ignaszak.

    The Brock University Professor of Chemistry is researching a way to monitor if tumours are expanding or shrinking by building upon a current procedure that’s already part of a patient’s ongoing treatment, helping oncologists bypass the need for imaging tests.

    “During immunotherapy or chemotherapy treatment, tubes of blood are collected and analyzed to see how the treatment is affecting the liver, kidneys or other systems,” she says.

    “We’re investigating how to look for a specific biomarker in this blood showing the presence of the breast cancer tumour so that the oncologist can immediately see if the therapy is working without having to use expensive imaging procedures.”

    Testing blood for the presence of tumour markers — proteins produced by cancerous cells or healthy cells in contact with cancerous cells — for early cancer detection has been around for a while.

    While these might help identify specific blood cancers like leukemia, blood testing alone is insufficient to detect and diagnose breast, pancreatic, lung and most other cancers, says Ignaszak.

    If anything unusual shows up, patients need to undergo further lab or imaging tests such as MRIs or CT scans.

    Ignaszak’s team is focusing on ways to monitor developments in late-stage breast cancer rather than early detection, since the level of cancer biomarkers isn’t high enough early on for biosensor technology to pick up.

    “The goal here is to assist oncologists in bypassing the delay of CT or MRI scans by catching molecular-level changes weeks or months before a physical tumour grows back,” she says.

    To that end, the team developed the prototype of a device that measures the level of a protein called progranulin (GP88), a relatively new biomarker for breast and other cancers. GP88 fuels cancer cells and has been implicated in drug resistance.

    GP88 enters the blood stream after it’s been secreted by the tumour cell, says Ignaszak.

    “Normally when therapy works, the tumour shrinks very fast, which means it’s shedding off into the blood less and less,” she says. “If the oncologist looks at the progression of blood samples and sees the decrease of GP88, it immediately shows the therapy is working.”

    Ignaszak and her team are using blood serum from both male and female patients to test out, and adjust, their prototype, taking a wide range of factors into consideration.

    The next step, anticipated sometime next year, will be to start the process of clinical trials, she says.

    Funding her research are the Government of Canada’s Natural Sciences and Engineering Research Council of Canada, Mitacs, the Canadian Space Agency and the Canadian Institutes of Health Research.

    Ignaszak leads the Ignaszak Research Group, which specializes in the study of electrochemistry, used in innovations such as the personal glucose sensor.

    In addition to detecting GP88 and other breast cancer markers in blood samples, the team is exploring the same approach for leukemia markers, blood coagulation markers and detection of Lyme disease-causing bacteria in urine.

    For more information or for assistance arranging interviews:

    *Melinda Cheevers, Communications Specialist, Brock University, [email protected] or 289-241-5855

    – 30 –


    Categories: Media releases